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1. Introduction
Thalassemias are a heterogenous group of genetic disorders, transmitted as autosomal 
recessive inheritance, in which the rate of hemoglobin production is partially or completely 
suppressed due to the reduced rate of synthesis of α- or β-chain, the two chains of adult hemo-
globin (Hb A) [1]. The molecular defects that cause thalassemia are located within the human 
globulin gene which encodes for alpha and beta globulin polypeptide chain of hemoglobin on 
chromosome numbers 16 and 11, respectively. These genetic molecular defects in thalassemia 
lead to reduced or no production of one globulin chain with the excess of the other resulting 
in alpha thalassemia when the alpha chain is affected and beta thalassemia when the beta 
chain is affected [2]. In thalassemia, the imbalance of globin chain synthesis leads to red cell 
damage resulting in destruction of red cells in the marrow (ineffective erythropoiesis) and 
peripheral circulation (hemolysis) [3]. In addition to pediatrician and hematologist, family 
physician and general practitioner need to know what thalassemia is, how it is diagnosed 
and differentiated from other hypochromic microcytic anemias, and what are the principles 
of treatment and prevention.
2. Epidemiology
Classically, thalassemia affecting population across thalassemic built which extends from the 
Mediterranean region through Middle East and Sub-Saharan Africa to South and Southeast 
Asian countries. Nowadays, thalassemia occurs all over the world because of continual 
migrations of population from these areas to western countries. Thalassemia affects both 
sexes equally, occurring approximately in 4.4% of every 10,000-live birth [4] and accounting 
for about 60,000–70,000 children each year who born with different types of thalassemia [5].
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3. Genetic bases and hemoglobin types
In the embryonic life, blood in the blood islands of the yolk sac produces specific types of 
hemoglobulin called Gower 1 composed of two zeta chains and two epsilon chain (ξ2ε2), 
Gower 2 composed of two alpha chains and two epsilon chains (α2ε2), and Portland hemo-
globulin composed of two zeta chains and two gamma chains (ξ2γ2). In the first trimester, 
definitive hematopoietic stem cell emerges from the ventral wall of the dorsal aorta which 
then migrates to fetal liver where fetal hemoglobin is produced (Hb F). Around the time of 
birth, hematopoietic stem cell migrates to the bone morrow which will become the main site 
of adult hemoglobin production for the rest of life. The switching from embryonic to fetal and 
then to adult hemoglobin occurs as a result of well-coordinated developmental stage due to 
specific expression of globin genes in Alpha and Beta globin loci [6]. Each type of hemoglo-
bin composes of four globin chains. Fetal hemoglobin has two alpha and two gamma chains 
(α
2
γ
2
) accounting for approximately 80% of hemoglobin at birth, while adult hemoglobin 
(Hb A1) has two alpha and two beta chains (α
2
β
2
) constituting the remaining 20%. While the 
Figure 1. Embryonic, fetal, and adult hemoglobin [7].
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switch on transition from gamma chain to beta chain production after birth, the hemoglobin 
A1 gradually replaces hemoglobin F, and at 6 months of age, Hb A1 constitutes about 97% 
and Hb F about 1%. The remaining small amount is of Hb A2 composed of two alpha and two 
delta chains (α
2
δ
2
) (Figure 1).
In alpha thalassemia, reduced or no production of alpha globin chains is usually caused by 
deletion of one or more of the genes responsible for its production. Deletion of one gene 
results in alpha thalassemia carrier state in which the patient is asymptomatic with normal 
hematological findings. Deletion of two genes results in alpha thalassemia trait or alpha thal-
assemia minor in which the patient has no or very mild anemia but with microcytosis. On the 
other hand, deletion of three genes results in significant production of hemoglobin H consist-
ing of four beta chain (β
4
), also called alpha thalassemia intermedia, which usually presents 
with hemolysis, microcytosis, and splenomegaly, while the deletion of the four genes results 
in the production of significant amount of hemoglobin Bart which consists of four gamma 
chain (γ
4
); Bart’s hemoglobin, also called alpha thalassemia major, definitely will result in 
hydrops fetalis.
Regarding the more common type of thalassemia, B thalassemia, more than 200 mutations, 
and rarely deletions, of the two genes responsible for the production of B chain can be crimi-
nated. In B thalassemia, the production of beta chain can range from normal to completely 
absent resulting in variable clinical presentations. In the one-gene defect, the patient has thal-
assemia minor, also called trait, in which the patient is asymptomatic apart from mild anemia 
(hemoglobin level is 2–3 g below the average of his age) and microcytosis. This is commonly 
mistaken as the more common iron deficiency anemia. If both genes are affected resulting in 
no or reduced production of beta chain, the patient has thalassemia major (when it is absent) 
or thalassemia intermedia when it is reduced. Thalassemia major is usually asymptomatic 
at birth because at this age, normally, the hemoglobin F is predominant. At 6 months of age, 
the patients present with severe anemia and hepatosplenomegaly. In patients with reduced 
production of beta chain, clinical spectrum will be beta thalassemia intermedia in which the 
patient will suffer less severe symptoms with the occasional requirement for blood transfu-
sion and he enjoys long life survival.
4. Consequences
The two major consequences of thalassemia major are severe anemia, resulting from inef-
fective erythropoiesis, and iron overload resulting from regular blood transfusion and also 
increasing the rate of iron absorption in small intestine. Almost all complications of thalas-
semia major can be attributed to these two factors. Examples of these complications include 
skeletal changes, hepatosplenomegaly, growth retardation, multiple endocrine failure, and 
cardiac problem. Additionally, blood transfusion for anemia and chelation therapy for iron 
overload represent a major burden on the patient and his family and on the health resources 
where its prevalence is high. The only hope for children implicated with thalassemia major is 
bone marrow transplantation when it is done early in life before complications occur.
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5. Hope for cure
Hematopoietic stem cell transplantation represents the only curative approach for those 
unlucky patients with thalassemia. Hematopoietic stem cells from a healthy donor replace the 
affected bone marrow and restore the normal hematopoiesis. The success rate is inversely cor-
related with the degree of iron overload and hepatic damage. The availability of healthy accept-
able donor is another problem especially in societies with small family size as in China [8].
In areas where thalassemia rate is high, determination of carrier rate by population screening 
and prenatal diagnosis associated with genetic counseling is very useful by allowing couples 
at risk to decide about their reproductive choice after explaining the nature of the disease and 
the associated risk of having an affected child. It is clear that the only way to stop thalassemia 
is to prevent the birth of affected child by making the premarital screening tests for thalas-
semia carrier state compulsory for the general population and providing counseling for the 
affected families. Implementation of effective program for thalassemia control adopted by 
health authority with the help of international agencies like World Health Organization is 
fundamental for effective control of thalassemia in countries where its prevalence is high.
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